Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.

Ehninger A, Kramer M, Röllig C, Thiede C, Bornhäuser M, von Bonin M, Wermke M, Feldmann A, Bachmann M, Ehninger G, Oelschlägel U.

Blood Cancer J. 2014 Jun 13;4:e218. doi: 10.1038/bcj.2014.39.

2.

CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.

Rollins-Raval M, Pillai R, Warita K, Mitsuhashi-Warita T, Mehta R, Boyiadzis M, Djokic M, Kant JA, Roth CG.

Appl Immunohistochem Mol Morphol. 2013 May;21(3):212-7. doi: 10.1097/PAI.0b013e318261a342.

PMID:
22914610
3.

Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.

Falini B, Sportoletti P, Brunetti L, Martelli MP.

Br J Haematol. 2015 Aug;170(3):305-22. doi: 10.1111/bjh.13409. Epub 2015 Apr 19. Review.

PMID:
25891481
4.

A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.

Angelini DF, Ottone T, Guerrera G, Lavorgna S, Cittadini M, Buccisano F, De Bardi M, Gargano F, Maurillo L, Divona M, Noguera NI, Consalvo MI, Borsellino G, Bernardi G, Amadori S, Venditti A, Battistini L, Lo-Coco F.

Clin Cancer Res. 2015 Sep 1;21(17):3977-85. doi: 10.1158/1078-0432.CCR-14-3186. Epub 2015 May 8.

5.

Acute myeloid leukemia: 2013 update on risk-stratification and management.

Estey EH.

Am J Hematol. 2013 Apr;88(4):318-27. doi: 10.1002/ajh.23404. Review.

6.

Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations.

Riccioni R, Pelosi E, Riti V, Castelli G, Lo-Coco F, Testa U.

Br J Haematol. 2011 Apr;153(1):33-42. doi: 10.1111/j.1365-2141.2011.08577.x. Epub 2011 Feb 20.

PMID:
21332708
7.

FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.

Wang L, Xu WL, Meng HT, Qian WB, Mai WY, Tong HY, Mao LP, Tong Y, Qian JJ, Lou YJ, Chen ZM, Wang YG, Jin J.

J Zhejiang Univ Sci B. 2010 Oct;11(10):762-70. doi: 10.1631/jzus.B1000052.

8.

High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation.

De Propris MS, Raponi S, Diverio D, Milani ML, Meloni G, Falini B, Foà R, Guarini A.

Haematologica. 2011 Oct;96(10):1548-51. doi: 10.3324/haematol.2011.043786. Epub 2011 Jul 26.

9.

FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.

Pollard JA, Alonzo TA, Gerbing RB, Woods WG, Lange BJ, Sweetser DA, Radich JP, Bernstein ID, Meshinchi S.

Blood. 2006 Oct 15;108(8):2764-9. Epub 2006 Jun 29.

10.

Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.

Dalal BI, Mansoor S, Manna M, Pi S, Sauro GD, Hogge DE.

Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):274-9. doi: 10.1016/j.clml.2012.01.003. Epub 2012 Apr 4.

PMID:
22481022
11.

Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor.

Riccioni R, Diverio D, Riti V, Buffolino S, Mariani G, Boe A, Cedrone M, Ottone T, Foà R, Testa U.

Br J Haematol. 2009 Feb;144(3):376-87. doi: 10.1111/j.1365-2141.2008.07491.x. Epub 2008 Nov 13.

PMID:
19036083
12.

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, Lichtenegger FS, Schneider S, Metzeler KH, Fiegl M, Spiekermann K, Baeuerle PA, Hiddemann W, Riethmüller G, Subklewe M.

Blood. 2014 Jan 16;123(3):356-65. doi: 10.1182/blood-2013-08-523548. Epub 2013 Dec 3.

13.

The surface molecular signature of leukemic cells is associated with NPM1 mutations and FLT3 -ITD in patients with de novo acute myeloid leukemia.

Su L, Gao SJ, Li W, Tan YH, Cui JW, Han W.

Acta Haematol. 2014;131(3):148-52. doi: 10.1159/000353663. Epub 2013 Oct 31.

PMID:
24192815
14.

Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.

How J, Sykes J, Gupta V, Yee KW, Schimmer AD, Schuh AC, Minden MD, Kamel-Reid S, Brandwein JM.

Cancer. 2012 Dec 15;118(24):6110-7. doi: 10.1002/cncr.27683. Epub 2012 Jun 26.

15.

Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation.

Mori Y, Yoshimoto G, Kumano T, Miyamoto T, Iino T, Takenaka K, Iwasaki H, Harada N, Kinukawa N, Nagafuji K, Teshima T, Shimoda K, Akashi K, Harada M.

Eur J Haematol. 2007 Jul;79(1):17-24.

PMID:
17598835
16.

Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.

Estey EH.

Am J Hematol. 2012 Jan;87(1):89-99. doi: 10.1002/ajh.22246.

17.

Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication.

Rickmann M, Krauter J, Stamer K, Heuser M, Salguero G, Mischak-Weissinger E, Ganser A, Stripecke R.

Ann Hematol. 2011 Sep;90(9):1047-58. doi: 10.1007/s00277-011-1231-2. Epub 2011 Apr 26.

18.

Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation.

Chen W, Konoplev S, Medeiros LJ, Koeppen H, Leventaki V, Vadhan-Raj S, Jones D, Kantarjian HM, Falini B, Bueso-Ramos CE.

Cancer. 2009 Dec 1;115(23):5481-9. doi: 10.1002/cncr.24610.

19.

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.

Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O, Biondi A, Biagi E, Bonnet D.

Leukemia. 2014 Aug;28(8):1596-605. doi: 10.1038/leu.2014.62. Epub 2014 Feb 7.

PMID:
24504024
20.

FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.

Ghosh K, Swaminathan S, Madkaikar M, Gupta M, Kerketta L, Vundinti B.

Ann Hematol. 2012 Nov;91(11):1703-12. doi: 10.1007/s00277-012-1509-z. Epub 2012 Jun 26.

PMID:
22733614

Supplemental Content

Support Center